Programs
Programs
AIM-HI leverages its positioning within the scientific and entrepreneurial communities to identify promising startups for investment. We consistently support companies led by best-in-class scientist-entrepreneurs around the globe.
In doing so, we challenge the status quo, in which only a small percentage of such companies ever make it into commercial ventures.
We measure the success of our investments not only in fiscal return, but in patient lives saved.
Please click on each company to read more of their story.
Stories From Our Companies
Enhancing surgery and diagnostics with unique, cancer-targeted molecular probes to improve outcomes and patients’ quality of life
Chimera Bio
Arming CAR-Ts with immunomodulatory payloads to counteract the tumor microenvironment, enabling CAR-T efficacy in solid tumors
A pre-clinical biotech company developing precision immunotherapies targeting the most common cancer-causing mutations
Developing a new class of small molecule drugs, molecular glue degraders (MGDs), that target previously undruggable disease targets
Developing next-gen therapeutics for improved patient outcomes via best-in-class approach for targeting disease driver, HDAC6
A breakthrough therapy for lethal cancers by deploying novel Cancer Terminator Viruses
Unique target and small molecules to treat different stages of cancer progression
Discovering, developing, and commercializing more effective and less toxic therapies for pediatric oncology
Localized cancer therapy for a more potent and significantly safer treatment
Harnessing the power of computational drug design for the identification of novel cancer therapeutics
A Specialty Pharmaceutical Company Advancing Cancer Treatment Through Safer Drug Delivery
Developing potential breakthrough therapies for patients with cancer by targeting cancer-specific vulnerabilities & co-dependencies in the tumor microenvironment
Targeting unique cancer-specific antigens using powerful antibody-drug-conjugates to deliver a lethal blow to cancer
Developing oral inhibitors of STAT3 as breakthrough therapies for cancer and fibrosis
(Nasdaq: TVRD)
Discovering and developing transformational therapeutics to address critical unmet patient needs in life-threatening diseases.
Supporting Entrepreneurs in STEM with Social Impact Funding
AIM-HI is on a mission to transform the non-profit impact investment landscape and break the barriers that hold back STEM innovations. We envision a new paradigm of philanthropy that empowers millions of lives with a powerful impact and a high-potential upside.
Why Support AIM-HI
An IRS-Approved Vehicle to Maximize Tax-Deductions & Make Direct Impact Investments in Mission-Based Companies
- Enables donors, foundations and nonprofits the opportunity to fund social impact, for-profit companies with tax-deductible dollars.
- Advance charitable mission beyond grant-making.
- Partner with leading research institutions to support early-stage STEM and social impact entrepreneurs.
Benefits:
- Income Tax Reduction and Capital Gains Mitigation
- Minimize Major Tax Event and Estate Tax
- Unlock Future Financing for Social Initiatives
- Recycling Philanthropic Capital to Magnify Social Impact
- Improved Sustainability of Social Enterprises
Summer Entrepreneurship Fellowship for Future Healthcare Leaders
The AIM-HI Accelerator Fund is joining forces with Georgetown Entrepreneurship to offer a 2025 Summer Fellowship Program for those passionate about pursuing a career in healthcare entrepreneurship, particularly in oncology. During this immersive learning opportunity, fellows will work closely with our portfolio companies and gain insights into how biotech companies are funded and the drug development process.
Program Highlights
Who Should Apply
Self-motivated and fast-learning individuals with a strong interest in becoming an entrepreneur but unsure of how/where to start, and able to commit primarily on-site during the summer program.
